These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 9419755)
41. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment. Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825 [TBL] [Abstract][Full Text] [Related]
42. Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. Ahn HJ; Kim YS; Kim JU; Han SM; Shin JW; Yang HO J Cell Biochem; 2004 Apr; 91(5):1043-52. PubMed ID: 15034938 [TBL] [Abstract][Full Text] [Related]
43. Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy. Xing H; Wang S; Hu K; Tao W; Li J; Gao Q; Yang X; Weng D; Lu Y; Ma D J Cancer Res Clin Oncol; 2005 Aug; 131(8):511-9. PubMed ID: 15924242 [TBL] [Abstract][Full Text] [Related]
44. [Antimitotic agents]. Fukuoka K; Saijo N Gan To Kagaku Ryoho; 1997 Sep; 24(11):1519-25. PubMed ID: 9309150 [TBL] [Abstract][Full Text] [Related]
46. Cytokinetic and morphologic differences in ovarian cancer cells treated with ET-18-OCH3 and the DNA-interacting agent, etoposide. Fujiwara K; Koike H; Ohishi Y; Shirafuji H; Kohno I; Modest EJ; Kataoka S Anticancer Res; 1997; 17(3C):2159-67. PubMed ID: 9216681 [TBL] [Abstract][Full Text] [Related]
47. Cytokinetics of a novel 1,2,3-triazene-containing heterocycle, 8-nitro-3-methyl-benzo-1,2,3,5-tetrazepin-4(3H)-one (NIME), in the human epithelial ovarian cancer cell line OVCAR-3. Jean-Claude BJ; Mustafa A; Damian Z; De Marte J; Vasilescu DE; Yen R; Chan TH; Leyland-Jones B Biochem Pharmacol; 1999 Apr; 57(7):753-62. PubMed ID: 10075081 [TBL] [Abstract][Full Text] [Related]
48. Estramustine resistance correlates with tau over-expression in human prostatic carcinoma cells. Sangrajrang S; Denoulet P; Millot G; Tatoud R; Podgorniak MP; Tew KD; Calvo F; Fellous A Int J Cancer; 1998 Aug; 77(4):626-31. PubMed ID: 9679768 [TBL] [Abstract][Full Text] [Related]
49. Vanadocenes as potent anti-proliferative agents disrupting mitotic spindle formation in cancer cells. Navara CS; Benyumov A; Vassilev A; Narla RK; Ghosh P; Uckun FM Anticancer Drugs; 2001 Apr; 12(4):369-76. PubMed ID: 11335794 [TBL] [Abstract][Full Text] [Related]
50. Estramustine sensitizes human glioblastoma cells to irradiation. Yoshida D; Piepmeier J; Weinstein M Cancer Res; 1994 Mar; 54(6):1415-7. PubMed ID: 8137240 [TBL] [Abstract][Full Text] [Related]
51. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Hartley-Asp B Prostate; 1984; 5(1):93-100. PubMed ID: 6694918 [TBL] [Abstract][Full Text] [Related]
52. 2-(Naphthalene-1-yl)-6-pyrrolidinyl-4-quinazolinone inhibits skin cancer M21 cell proliferation through aberrant expression of microtubules and the cell cycle. Wu YC; Hour MJ; Leung WC; Wu CY; Liu WZ; Chang YH; Lee HZ J Pharmacol Exp Ther; 2011 Sep; 338(3):942-51. PubMed ID: 21652781 [TBL] [Abstract][Full Text] [Related]
53. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493 [TBL] [Abstract][Full Text] [Related]
54. Estramustine and estrone analogs rapidly and reversibly inhibit deoxyribonucleic acid synthesis and alter morphology in cultured human glioblastoma cells. Piepmeier JM; Keefe DL; Weinstein MA; Yoshida D; Zielinski J; Lin TT; Chen Z; Naftolin F Neurosurgery; 1993 Mar; 32(3):422-30; discussion 430-1. PubMed ID: 8384327 [TBL] [Abstract][Full Text] [Related]
55. Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells. Jakus J; Yeudall WA Oncogene; 1996 Jun; 12(11):2369-76. PubMed ID: 8649777 [TBL] [Abstract][Full Text] [Related]
56. Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine. Wang M; Tew KD; Stearns ME Anticancer Res; 1987; 7(6):1165-71. PubMed ID: 3327449 [TBL] [Abstract][Full Text] [Related]
57. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. Nishio K; Arioka H; Ishida T; Fukumoto H; Kurokawa H; Sata M; Ohata M; Saijo N Int J Cancer; 1995 Nov; 63(5):688-93. PubMed ID: 7591286 [TBL] [Abstract][Full Text] [Related]
58. Antiproliferative and apoptotic effects of zinc-citrate compound (CIZAR(R)) on human epithelial ovarian cancer cell line, OVCAR-3. Bae SN; Lee YS; Kim MY; Kim JD; Park LO Gynecol Oncol; 2006 Oct; 103(1):127-36. PubMed ID: 16624386 [TBL] [Abstract][Full Text] [Related]
59. Growth of prostatic cancer cells, DU 145, as multicellular spheroids and effects of estramustine. Essand M; Nilsson S; Carlsson J Anticancer Res; 1993; 13(5A):1261-8. PubMed ID: 8239495 [TBL] [Abstract][Full Text] [Related]
60. Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression. Sangrajrang S; Denoulet P; Laing NM; Tatoud R; Millot G; Calvo F; Tew KD; Fellous A Biochem Pharmacol; 1998 Feb; 55(3):325-31. PubMed ID: 9484799 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]